Categories
Business Culture Economics Lifestyle Perspectives Regulations & Security

AM Best affirms Credit Ratings of Starr International Company, Inc.’s insurance subsidiaries

OLDWICK, N.J. — (BUSINESS WIRE) — #insuranceAM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a+” (Excellent) of the insurance subsidiaries of Starr International Company, Inc. (SICO) (Switzerland), a private investment holding company. The outlook of these Credit Ratings (ratings) is stable. These rating actions apply to the members of Starr International Group (SIG) and Starr Insurance & Reinsurance Limited (SIRL) (Bermuda).

 

The ratings of the members of SIG reflect their balance sheet strength, which AM Best assesses as strongest, as well as their adequate operating performance, favorable business profile and appropriate enterprise risk management (ERM). Members of SIG include Starr Indemnity & Liability Company, Starr Surplus Lines Insurance Company and Starr Specialty Insurance Company. These companies are all domiciled in Dallas, TX.

 

The ratings of SIRL and its members reflect their balance sheet strength, which AM Best assesses as strongest, as well as their adequate operating performance, favorable business profile and appropriate ERM. Members of SIRL include Starr Property & Casualty Insurance (China) Company, Limited; Starr International Insurance (Asia) Limited (Hong Kong); Starr International Insurance (Singapore) Pte. Ltd; Starr International (Europe) Limited (United Kingdom); Starr International Insurance (Switzerland) AG (Switzerland) and Starr Europe Insurance Limited (Malta).

 

The operations of SIG and SIRL support a business profile that is well-diversified internationally and by product exposures. The groups continue to report strong growth trends in their key markets. Overall underwriting results are in line with the commercial casualty composite five-year average combined ratio. The groups have sustained the strongest levels of risk-adjusted capitalization on a consolidated and per-entity basis, as measured by Best’s Capital Adequacy Ratio (BCAR), which is further supported by favorable liquidity metrics. AM Best also notes that each group maintains above-average allocations to alternative asset classes, relative to composite peers, including private equity and debt funds, real estate funds and hedge funds, which are managed by affiliated investment management companies using external asset managers.

 

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2023 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Michael Venezia
Senior Financial Analyst

+1 908 882 2414
michael.venezia@ambest.com

Christopher Sharkey
Associate Director, Public Relations

+1 908 882 2310
christopher.sharkey@ambest.com

Erik Miller
Director
+1 908 882 2120
erik.miller@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
al.slavin@ambest.com

Categories
Business Culture Digital - AI & Apps Economics Lifestyle Science Sports & Gaming Technology Travel & Leisure Weather & Environment

DaleBoot partners with Aetrex to offer custom ski boots based on 3D foot scans

Partnership marks the first use of 3D foot scanning technology in custom ski gear

 

TEANECK, N.J. — (BUSINESS WIRE) — Aetrex, Inc., a global market leader in foot scanning technology and data-driven orthotics and comfort footwear, on Tuesday announced its partnership with custom ski boot manufacturer DaleBoot.

 

Leveraging Aetrex’s Albert 2 Pro foot scanning technology, DaleBoot will transition from manually measuring customer’s feet to using automated 3D foot scan data to design custom ski boots, improving fit accuracy and customer satisfaction and reducing refitting rates during a compact winter retail season.


After years of testing several foot scanning technologies, DaleBoot selected Aetrex technology for its accuracy and ease of use. Aetrex’s scanners use a pure computer vision model to create the most accurate 3D reconstruction of the foot available on the market. DaleBoot customers will complete a 20 second foot scan on the Albert 2 Pro and answer questions on ski experience, previous discomfort with ski boots and preferred snow conditions. DaleBoot will then use the 3D foot scan data and customer-reported information to develop a pair of custom ski boots with a personalized-fit shell, a fully custom liner and in-boot and on-ski stance balance and alignment, in under a week.

 

“Most skiiers consider wearing uncomfortable ski boots an unavoidable experience when hitting the slopes. But any footwear, including ski boots, designed to fit your feet should never be painful. Our partnership with DaleBoot aims to make that a reality by bringing detailed, accurate 3D measurements and data-driven insights to the ski boot development process,” said Larry Schwartz, CEO of Aetrex.

 

As of August 2023, Aetrex scanners are currently in use at 8 DaleBoot stores, including Salt Lake City, UT, and Kitzbuehel, Austria locations. The company plans to bring Aetrex foot scanners to all 60 points of distribution in ski shops around the world.

 

“Our commitment to continuous innovation has made DaleBoot the custom boot manufacturer of choice for the industry since 1969. Our customers know they can always count on us for the latest and greatest in ski boot technology,” said Rob Graham, CEO of DaleBoot. “Partnering with Aetrex during this next phase of our evolution makes our boots more personalized and data-driven than ever before.”

 

To learn more, visit www.aetrex.com/technology or contact Aetrex National Accounts Manager Justin Dyszelski at jdyszelski@aetrex.com to discuss leveraging Aetrex technology for developing snow sports gear.

 

About Aetrex

Aetrex, Inc. is widely recognized as a global leader in foot scanning technology and data-driven orthotics and comfort footwear. Aetrex has developed state-of-the-art foot scanning devices, including Albert, Albert 2 Pro and Albert 3DFit (2022 and 2023 CES Innovation Award Honorees), Albert Pressure and iStep, designed to accurately measure feet and determine foot type and pressure points. Since 2002, Aetrex has placed over 12,000 scanners worldwide that have performed more than 50 million unique customer foot scans, currently averaging more than 2.5 million scans a year.

 

The company is renowned for its over-the-counter orthotics – the worlds #1 premium foot orthotic. With fashion, function and quality at the forefront, Aetrex also designs and manufactures stylish, performance footwear. Based in New Jersey, Aetrex is consistently named one of New Jersey’s Top 100 Privately Held Companies and was also included in NJBIZ’s Top 30 Manufacturing Companies. It has remained privately owned by the Schwartz family for three generations. For additional information, visit www.aetrex.com.

 

About DaleBoot

Since its inception in 1969, DaleBoot has been highly focused on designing and manufacturing fully custom, high performance ski boots. With its factory and North American Headquarters based in Salt Lake City, and their European HQ located in the heart of the Alps in Kitzbuehel, Austria, DaleBoot provides worldwide coverage through its exclusive retail partner network. With 14 patents issued in its name, the company has chartered a course to address real customer issues, facing 85% of the skiing population, who experience problems, from large to small, with their ski boots. The DaleBoot process includes a complete athletic and bio-mechanic assessment, a series of 3D measurements, shell and liner customization, in-boot stance balance and alignment, and true on-ski cant correction. The result is a high performance ski boot that fits comfortably and is exciting to ski.

 

Founded by Mel Dalebout, an alternate for the 1952 U.S. Olympic Ski Team, and Intermountain Ski Hall of Fame inductee, the company was purchased by Rob Graham, a former U.S. freestyler, in 2007. Graham’s passion for the sport and deep business and orthopaedic acumen has propelled the company forward in terms of ski boot design and development, while establishing a new line of business dedicated to the design and manufacturing of devices used for orthopaedic surgeries. The company remains independently owned and operated. For more information on DaleBoot, please visit www.daleboot.com.

Contacts

Simone Migliori

Matter Communications

aetrex@matternow.com

Categories
Business Culture Digital - AI & Apps Energy Government Lifestyle News Now! Perspectives Politics Regulations & Security Science Technology Weather & Environment

Best’s Review looks ahead to 2024 key issues

OLDWICK, N.J. — (BUSINESS WIRE) — In a new article, Best’s Review speaks to experts about what they see as the insurance industry’s top issues in the coming year.

 

Hot topics include natural catastrophes and climate risk, generative artificial intelligence, cyber risk, litigation and nuclear verdicts, as well as the U.S. presidential election.

 

The insurance workforce is also in the spotlight as layoff announcements have accelerated. Read the full story in “Insurers Look Ahead to 2024 and Key Issues: Catastrophes, Inflation, Layoffs, AI and More.”

 

Best’s Review is AM Best’s monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. The complete content of Best’s Review is available here.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2023 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Patricia Vowinkel
Executive Editor, Best’s Review®
+1 908 882 1771
patricia.vowinkel@ambest.com

Categories
Business Culture Entertainment News International & World Lifestyle Travel & Leisure

The Piyush Mishra Project Ballimaaraan to tour USA with Para Share Entertainments

ATLANTA — (BUSINESS WIRE) — #Bollywood–Start of 2024 is going to be nothing short of an adventure as The Piyush Mishra Project – Ballimaaraan, a live concert is all set to tour the United States for the very first time via Para Share Entertainments (PSE).

 

PSE is delighted to work with Tamboo and Trinity to make this project see its success in the United States. This band’s popularity among youth stems from its seamless fusion of retro and contemporary music, creating a rebellious vibe with free-flowing Hindi lyrics that evoke engaging conversations. Book tickets here.

 

For an ever growing Indian American diaspora who represent one of the largest (5 million+) immigrant groups in the US, PSE shows make a positive impact. Second generation desis and students of Indian origin make the current audience diverse as it gets. The Piyush Mishra Project – Ballimaaraan has had a busy 2023 in India. With 10 shows across several cities, the concerts are scheduled to be held at state of art performing art centers and are designed to give the audience a memorable experience.

 

The US tour 2024

Houston, Washington DC, Detroit, Chicago, Atlanta, Seattle, Bay Area (San Jose), Dallas, Connecticut, New York / New Jersey

 

About PSE

Para Share Entertainments (PSE) is a digitally-powered US-based startup that produces LIVE shows around the world. Headquartered in Atlanta, GA, PSE is a market leader with a growing audience.

 

Until now, PSE has catered to 250,000+ patrons in the last 5 years. They aspire to impact 1 billion people in the next 3 years. PSE aims to uplift global mental health amidst chaos and uncertain times.

 

Founded in 2017 by Harshad Parashare, PSE has produced 300+ in-person shows. PSE carefully curates creative and engaging experiences for our audiences without compromising on their quality. The team at PSE is now gearing up for an action-packed 2024. PSE wants to engage with the community and expand its horizons to redefine entertainment by breaking paradigms. Their vision is to revolutionize the way live events are organized without hampering the quality of the experience. With 100% success rate when it comes to working with United States Citizenship & Immigration Services, PSE collaborates with partners and artists from all parts of the world.

Contacts

Harshad Parashare

Founder, CEO

harshad@parashare.com
470 253 4822

Shilpa Mehta

Product Manager, Partnerships & Associations

shilpa@parashare.com

Categories
Business Culture Healthcare Lifestyle News Now! Programs & Events Science Technology

MATTER opens applications for accelerator focused on reducing maternal mortality in the US

Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support cohort of women’s health startups; including $125,000 of investment for each selected company

CHICAGO — (BUSINESS WIRE) — MATTER, the premier healthcare incubator and innovation hub, has opened applications for the second 51 Labs, an accelerator focused on women’s health.

 

This year’s program focuses on preventing maternal mortality in the U.S. before, during and after birth and receives support from Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker.

 

Earlier this year, the Centers for Disease Control and Prevention published a report showing that the maternal mortality rate in the U.S. worsened by 40 percent from 2020 to 2021.1 The maternal mortality rate is now the highest in the U.S. since 1965 and is far worse than other industrialized nations.

 

While all ages and races saw an increase in maternal mortality in 2021, many inequities still exist due to a variety of factors, including but not limited to access to quality care, socioeconomic status, race and education level. For example, Black women are three times as likely to die from pregnancy or pregnancy-related causes as white women in the U.S.2

 

“51 Labs is designed to address gaps in investment and innovation in women’s health,” said Steven Collens, CEO of MATTER. “We are pleased to partner with seven key industry stakeholders to help a cohort of startups advance solutions to help address the maternal mortality crisis in the U.S.”

 

The Laerdal Million Lives Fund, a global venture capital fund dedicated to transformative technologies that can help save lives, will serve as a capital partner for this cohort of 51 Labs companies. “Many maternal deaths are preventable. By investing in enabling technologies and digital solutions that can drive early interventions with high life saving potential and quality improvement initiatives, we can help scale companies working in this critical area,” said Becca Shmukler, principal of Laerdal Million Lives Fund.

 

The second cohort of the 51 Labs accelerator will address the question:

 

How can we prevent maternal mortality in the U.S. before, during and after birth?

The program will have three tracks: 1) supporting access to regular prenatal care to identify and mitigate potential risk factors earlier; 2) lowering the incidence of maternal health complications; and 3) supporting mothers during the 12 months after giving birth.

 

“It’s critically important to support innovative solutions to help moms and babies thrive,” said Dr. Monica Berner, chief clinical officer for Health Care Service Corporation. “Earlier this year, HCSC launched an expanded maternal and infant health initiative to improve health outcomes by increasing access to care, reducing care gaps, and educating and engaging residents on a community level. This 51 Labs program is another way we can help support other innovators who are seeking to tackle this critical issue.”

 

Applications for the 12-week accelerator are now open. Participating startups will benefit from one-on-one mentoring with industry experts, workshops, interactive roundtable discussions, forums and more. Additionally, each of the selected companies will receive an investment of $125,000, including $100,000 cash from the Laerdal Million Lives Fund and $25,000 of services from MATTER.

 

The program will culminate with a final showcase in May 2024.

 

For more information, email 51labs@matter.health.

 

About MATTER

At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 800 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.

 

About HCSC

Health Care Service Corporation is the country’s largest customer-owned health insurer, serving more than 18.6 million members in its health plans in Illinois, Montana, New Mexico, Oklahoma and Texas. A Mutual Legal Reserve Company, HCSC is an independent licensee of the Blue Cross and Blue Shield Association.

 

About Laerdal Million Lives Fund

The Million Lives Fund invests in entrepreneurs who are developing and deploying new, emerging technologies capable of saving lives and enhancing healthcare quality and outcomes regardless of demographics or geography. The $100 million fund targets digital health and technology companies whose solutions can improve mortality rates and help reach its goal of helping to save 1 million lives annually by 2030. Investments span across medical education innovations to early interventions, therapeutics and tech-enabled care models. For more information, visit www.laerdalmillionlives.com.

 

About BayCare

BayCare is a leading not-for-profit healthcare system that connects individuals and families to a wide range of services at 16 hospitals and hundreds of other convenient locations throughout the Tampa Bay and central Florida regions. The system is West Central Florida’s largest provider of behavioral health and pediatric services and its provider group, BayCare Medical Group, is one of the largest in the region. BayCare’s diverse network of ambulatory services includes laboratories, imaging, surgical centers, BayCare Urgent Care locations, wellness centers and one of Florida’s largest home care agencies, BayCare HomeCare. Its Medicare Advantage insurance, BayCarePlus, is among the region’s few 5-star-rated plans and the system is ranked in the top 20 percent of large health systems in the country by FORUTNE/Merative™. BayCare’s mission is to improve the health of all it serves through community-owned, health care services that set the standard for high-quality, compassionate care.

 

About Parkview Health

Parkview Health is a not-for-profit, community-based health system serving a northeast Indiana and northwest Ohio population of more than 1.3 million. Parkview Health’s mission is to improve health and inspire well-being in the communities it serves. With more than 16,000 co-workers, it is the region’s largest employer. Parkview Health includes 13 hospitals and an extensive network of primary care and specialty care physicians. The flagship Parkview Regional Medical Center campus includes services such as the Parkview Packnett Family Cancer Institute, Parkview Heart Institute, Samaritan flight and ground transport program, Parkview Ortho Hospital, a certified stroke center, verified adult and pediatric trauma centers, Women’s & Children’s Hospital and an outpatient services center. Parkview has been named one of America’s Best-In-State Employers by Forbes and made Newsweek’s list of Top 100 Most Loved Workplaces.

 

About University of Chicago Medicine

The University of Chicago Medicine, with a history dating back to 1927, is one of the nation’s leading academic medical institutions. UChicago Medicine comprises the University of Chicago Medical Center, which offers a full range of primary and specialty care for adults and children through more than 40 institutes and centers; Ingalls Memorial, a community-based hospital and outpatient facility; a micro-hospital in northwest Indiana, a network of outpatient clinics and physician practices throughout Chicagoland and Northwest Indiana; the Pritzker School of Medicine, one of the top medical schools in the nation; and the University of Chicago Biological Sciences Division, with an affiliated 12 Nobel Prize winners in physiology or medicine.

 

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

 

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

 

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, Twitter and Facebook.

 

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

_____________

1Maternal Mortality Rates in the United States, 2021,” Centers for Disease Control and Prevention, 2023.

2U.S. Maternal Mortality Hits Highest Level Since 1965,” The Wall Street Journal, 2023.

Contacts

Julia Cremin

jcremin@pcipr.com
331-333-2928

Categories
Business Culture Economics Healthcare International & World Lifestyle News Now! Science

Merck Animal Health receives positive CVMP opinion for an injectable formulation of BRAVECTO® (Fluralaner) for use in dogs

RAHWAY, N.J. — (BUSINESS WIRE) — Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO® (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs.

 

The CVMP recommends the product for approval for the treatment and persistent killing of fleas (Ctenocephalides felis and Ctenocephalides canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, Ixodes hexagonus, and Dermacentor reticulatus) for 12 months. If the European Commission (EC) adopts the recommendation, this injectable formulation of BRAVECTO can be used by or under the supervision of a veterinarian and for administration to dogs and puppies six months of age and older.

 

“Since our initial launch of BRAVECTO nearly a decade ago, Merck Animal Health has been committed to bringing innovations to our customers that protect pets longer from flea and tick infestations and the associated health risks,” said Rick DeLuca, executive vice president and president, Merck Animal Health. “With today’s positive opinion of this injectable formulation of BRAVECTO, the first and only once-yearly injectable flea and tick medication, pet owners are one step closer to a new, convenient option to help ensure year-round comprehensive protection from fleas and ticks without the need for administering multiple doses of medication.”

 

Certain ticks can transmit serious infections in dogs. Many ticks can live in both warm and cold temperatures and are known to feed on dogs,1 making continuous year-round protection of utmost importance for pets and people.

 

“Though people often think of flea and tick season during the summer months, studies have shown that while fleas and ticks are most active from early spring through the fall, they can be a threat year-round,” said Holger Lehmann, vice president, Pharmaceutical Research & Development, Merck Animal Health. “If approved, a once-yearly dosing of BRAVECTO injectable can provide a long duration of protection, simplifying care for both pet owners and veterinarians. This promotes compliance and helps ensure continuous protection.”

 

Based on the CVMP’s recommendation, the EC is expected to issue a decision for marketing authorization in the European Union (EU) during the first quarter of 2024.

 

About BRAVECTO® (fluralaner)

Since its introduction in 2014, BRAVECTO has provided longer-lasting flea and tick protection, with more than 300 million doses distributed in more than 100 countries. BRAVECTO is available in a variety of formulations, including products for both dogs and cats.

 

The flea and tick life cycles can also last for months and missed doses of monthly treatments may leave gaps in protection.

 

Providing pets with continuous flea and tick protection is essential – whether the pet goes outside or not. Contrary to popular belief among pet parents, fleas and ticks are not only active in the spring and summer months, but they are a year-round risk.

 

Fleas and ticks can easily infest dogs and cats. They also can bite and pose health risks to human family members whether at home or outdoors. Ticks can spread serious diseases including rickettsiosis, anaplasmosis and borreliosis (Lyme disease), while fleas are the most common external parasite found on pets and can transmit bartonellosis (Cat Scratch disease) and tapeworms.

 

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (Formerly Twitter) and Instagram.

 

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

 

References

[1] Probst J, Springer A, Topp AK, Bröker M, Williams H, Dautel H, Kahl O, Strube C. Winter activity of questing ticks (Ixodes ricinus and Dermacentor reticulatus) in Germany− Evidence from quasi-natural tick plots, field studies and a tick submission study. Ticks and Tick-borne Diseases. 2023 Nov 1;14(6):102225.

Contacts

Media:

Kim Gorode

(973) 255-8904

Kim.Gorode@merck.com

Investor:

Peter Dannenbaum

(732) 594-1579

Categories
Business Digital - AI & Apps Economics Lifestyle Regulations & Security Technology

NICE Actimize recognized as Category Leader in the Chartis KYC Data and Solutions 2023 Market Update and Vendor Landscape Report

Measured across five unique solution functions, NICE Actimize scored highly in KYC risk scoring capabilities as well as reporting and dashboarding, and customer onboarding

 

 

HOBOKEN, N.J. — (BUSINESS WIRE) — #NICENICE Actimize, a NICE (NASDAQ: NICE) business, has been recognized by Chartis Research as a Category Leader in KYC solutions in its recently released KYC Data and Solutions 2023 Market Update and Vendor Landscape Report. The Chartis KYC RiskTech Quadrant® rated vendors across Market Potential and Completeness of Offering criteria which included 35 vendors of KYC solutions featured in this report. Chartis Research, part of Infopro Digital, is a leading provider of research and analysis on the global market for risk technology.

NICE Actimize achieved high scores across various parameters, including reporting and dashboarding, KYC risk scoring, customer profile enrichment with additional data, customer onboarding and maintenance. Most notably, NICE Actimize achieved a “four-star” rating for the category of KYC risk scoring. Other characteristics influencing the ranking position were market potential attributes, including customer satisfaction, market penetration, growth strategy, business model, and financials.

 

“NICE Actimize has continued to build out its KYC offering across cloud and on-premise deployments, developing its simulation and model and entity risk capabilities,” said Ahmad Kataf, Senior Research Specialist at Chartis Research. “Its strong partnership strategy reinforces its position as a hub for a flexible financial crime compliance marketplace, and it has also demonstrated continued growth on top of its already strong market penetration. All these factors are reflected in its category leader positioning in our KYC Solutions quadrant.”

 

“NICE Actimize’s AI-powered KYC/CDD solutions manage critical compliance challenges while providing complete customer lifecycle coverage without compromising customer experience,” said Craig Costigan, CEO, NICE Actimize, “As our financial services organizations place stronger emphasis on determining risk, our entity risk approach offers an unmatched ability to access true and transparent business intelligence around customers and entities while managing critical compliance challenges.”

 

In addition to offering complete customer lifecycle risk coverage, NICE Actimize’s next-generation KYC/CDD solution includes integrated data intelligence, identity resolution, extensive out-of-the-box risk models, dynamic segmentation and risk scoring, simulation, and full auditability to help organizations fully understand their customers, their customers’ connections, and any associated risks.

 

NICE Actimize was recently positioned number fifteen in Chartis’ comprehensive list of top 100 global risk and compliance technology vendors in the 2024 Chartis RiskTech100 report.

 

For further information on NICE Actimize solutions for Know Your Customer / KYC solutions, including white papers and e-books, please visit its web site here.

 

About Chartis

Chartis Research is the leading provider of research and analysis on the global market for risk technology. It is part of Infopro Digital, which owns market-leading brands such as Risk and WatersTechnology. The goal of Chartis Research is to support enterprises as they drive business performance through improved risk management, corporate governance and compliance, and to help clients make informed technology and business decisions by providing in-depth analysis and actionable advice on virtually all aspects of risk technology.

 

RiskTech Quadrant®, RiskTech100® and FinTech QuadrantTM are registered trademarks of Infopro Digital Services Limited (http://www.chartis-research.com).

 

About NICE Actimize

NICE Actimize is the largest and broadest provider of financial crime, risk and compliance solutions for regional and global financial institutions, as well as government regulators. Consistently ranked as number one in the space, NICE Actimize experts apply innovative technology to protect institutions and safeguard consumers and investors assets by identifying financial crime, preventing fraud and providing regulatory compliance. The company provides real-time, cross-channel fraud prevention, anti-money laundering detection, and trading surveillance solutions that address such concerns as payment fraud, cybercrime, sanctions monitoring, market abuse, customer due diligence and insider trading. Find us at www.niceactimize.com, @NICE_Actimize or Nasdaq: NICE.

 

About NICE

With NICE (Nasdaq: NICE), it’s never been easier for organizations of all sizes around the globe to create extraordinary customer experiences while meeting key business metrics. Featuring the world’s #1 cloud native customer experience platform, CXone, NICE is a worldwide leader in AI-powered contact center software. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, partner with NICE to transform – and elevate – every customer interaction. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

 

Forward-looking statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Costigan, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media Contact:

Cindy Morgan-Olson, +1 646 408 5896, ET, media@nice.com

Investors:

Marty Cohen, +1 551 256 5354, ET, ir@nice.com
Omri Arens, +972 3 763 0127, CET, ir@nice.com

Categories
Business Culture Economics Healthcare Lifestyle Perspectives Regulations & Security Science

Kirby McInerney LLP announces the filing of a securities class action on behalf of Outlook Therapeutics, Inc. (OTLK) investors

NEW YORK — (BUSINESS WIRE) — $OTLK #classactionlawsuit — The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) securities during the period from Dec. 29, 2022 through Aug. 29, 2023, inclusive (the “Class Period”). Investors have until Jan. 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

 

Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The Company’s lead product candidate is ONS-5010, an ophthalmic formulation of the antibody bevacizumab for the treatment of wet age-related macular degeneration (“wet AMD”) and other retina diseases.

 

In August 2021, Outlook announced the topline readout of data from its pivotal Phase 3 NORSE TWO trial of ONS-5010 for the treatment of wet AMD. According to the Company, this data, among other things, “demonstrated clinically relevant and highly statistically significant results” that supported the submission of a biologics license application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for ONS-5010 for the treatment of wet AMD, which the Company planned to submit to the FDA in the first quarter of 2022. In March 2022, Outlook announced that it had submitted the ONS-5010 BLA to the FDA.

 

In May 2022, the Company voluntarily withdrew the ONS-5010 BLA to provide additional information requested by the FDA. Following receipt of further correspondence from the FDA, the Company purportedly confirmed the additional information necessary to re-submit the BLA for ONS-5010 and resubmitted the BLA in August 2022.

 

On August 30, 2023, Outlook announced that the FDA had issued a complete response letter to the ONS-5010 BLA. The Company advised that the FDA could not approve the BLA during this review cycle due to several issues. On this news, the price of Outlook shares declined by $1.141 per share, or approximately 80.92%, from $1.41 per share to close at $0.269 on August 30, 2023.

 

The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose that: (i) there was a lack of substantial evidence supporting ONS-5010 as a treatment for wet AMD; (ii) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls and other manufacturing issues for ONS-5010, which remained unresolved at the time the ONS-5010 BLA was re-submitted to the FDA; (iii) as a result of all the foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its present form; and (iv) accordingly, ONS-5010’s regulatory and commercial prospects were overstated.

 

If you purchased or otherwise acquired Outlook securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

 

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com.

 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

Thomas W. Elrod, Esq.

212-699-1180

https://www.kmllp.com
investigations@kmllp.com

Categories
Business Digital - AI & Apps Lifestyle Technology

Desktop Metal now shipping the Figur G15 – a Digital Sheet Metal Forming machine that eliminates the need for custom tooling

  • The Figur G15 uses patent-pending Digital Sheet Forming (DSF) technology in which a software-driven ceramic toolhead on a gantry shapes standard sheet metal into parts with up to 2,000 lbs of force
  • With a maximum sheet size of 1600 x 1200 mm (63.0 x 47.2 in), the Figur G15 delivers parts with a draw depth up to 400 mm (16 in) in Z without custom forming tools, molds, dies, or presses
  • The G15 supports forming a range of metals and sheet thicknesses – including steel up to 2.0 mm and aluminum up to 2.5 mm – and delivers a high quality surface finish
  • Manufacturers now have a competitive way to offer formed sheet metal parts and products quickly for automotive, appliance, and aerospace applications without the high startup and development costs normally associated with sheet metal fabrication
  • First shown at IMTS 2022, the Figur G15 has sold out of its initial manufacturing run and is accelerating production to meet demand
  • A video showcasing how Saltworks will be using the Figur G15 is available at TeamDM.com/Saltworks

 

 

BOSTON — (BUSINESS WIRE) — #3Dprinting — Desktop Metal (NYSE: DM),a global leader in Additive Manufacturing 2.0 technologies for mass production, today announced the first commercial shipments of the Figur G15, an innovative Digital Sheet Forming (DSF) machine tool, to Saltworks Fab, a Florida-based automotive restoration and hot rod company.

 

Satworks is installing two Figur G15 platforms at its Sarasota, Florida facility to accelerate its auto restoration business and expand access to metal forming services to new customers. The company often creates metal body panels that are no longer commercially available with manual hammering and laborious forming processes.

Investing in the Figur G15, the company will dramatically reduce production times while also having the flexibility of digital manufacturing to create complex shapes, efficient one-offs, or produce short-runs of designs. Saltworks recently demonstrated the capabilities of the Figur G15 at the SEMA Show in Las Vegas, where the team exhibited the entire side body of a Mercedes Gullwing created of 6061 aluminum panels formed on the G15 in under 10 hours for the entire 15-piece assembly.

 

Our team has over 100 years of combined metal-shaping experience, and we’re excited to bring the latest digital metal forming technology in-house,” said David Jacobsen, CEO of Saltworks Fab. “The Figur G15 buys us time. It allows us to bring vintage vehicles back to their former glory while also enabling us to enter a whole new level of business helping customers that currently don’t have the ability or resources to form metal. Figur G15 allows us to expand access to metal-shaping services to a broader variety of small businesses, design shops, and self-builders.”

 

The Figur G15 is the first commercially available machine tool platform to shape sheet metal on demand without custom tooling. Introduced at the 2022 International Manufacturing Technology Show (IMTS) in Chicago, the Figur G15 uses patent-pending DSF technology in which a software-driven ceramic toolhead on a gantry shapes standard sheet metal into parts with up to 2,000 lbs of forming force without tooling, with software that simplifies the creation of sheet metal part production.

 

Recently, custom classic car influencer Rob Ida of Rob Ida Concepts in New Jersey posted on Instagram @rob_ida about how he is using the Figur G15 technology to create components for a 1955 Tucker Carioca, a vehicle concept from legendary carmarker Preston Tucker that never made it from drawing to production.

 

The response to Figur G15 from the market across a wide variety of sectors has been exciting,” said Justin Nardone, CEO of Figur, a Desktop Metal brand. “The G15 eliminates a lot of the work required when forming metal, such as the design and manufacturing of tools and dies. Our system produces designs quickly, accurately, and repeatedly, so manufacturers are able to focus on the craftsmanship of design while getting their products to market faster and more efficiently.”

 

Saltworks is planning to purchase two additional G15 systems, for a total of four, to join its initial fleet in the near future with plans to run all four machines over three shifts to keep up with demand.

To learn more about Figur, visit figur.desktopmetal.com.

 

About Desktop Metal:

Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products. Our innovative 3D printers, materials, and software deliver the speed, cost, and part quality required for this transformation. We’re the original inventors and world leaders of the 3D printing methods we believe will empower this shift, binder jetting and digital light processing. Today, our systems print metal, polymer, sand and other ceramics, as well as foam and recycled wood. Manufacturers use our technology worldwide to save time and money, reduce waste, increase flexibility, and produce designs that solve the world’s toughest problems and enable once-impossible innovations. Learn more about Desktop Metal and our #TeamDM brands at www.desktopmetal.com.

 

Forward-looking statements:

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in these communications, including statements regarding Desktop Metal’s future results of operations and financial position, financial targets, business strategy, and plans and objectives for future operations, are forward-looking statements. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: risks associated with the integration of the business and operations of acquired businesses; Desktop Metals’ ability to realize the benefits from cost saving measures; supply and logistics disruptions, including shortages and delays. For more information about risks and uncertainties that may impact Desktop Metal’s business, financial condition, results of operations and prospects generally, please refer to Desktop Metal’s reports filed with the SEC, including without limitation the “Risk Factors” and/or other information included in the Form 10-Q filed with the SEC on August 3, 2023, and such other reports as Desktop Metal has filed or may file with the SEC from time to time. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

Investor Relations:

(857) 504-1084

DesktopMetalIR@icrinc.com

Media Relations:

Sarah Webster

(313) 715-6988

sarahwebster@desktopmetal.com

Categories
Business Culture Economics Lifestyle News Now! Regulations & Security

Bluevine surpasses $1 billion in small business deposits

Trusted By Over 500,000 SMBs, Bluevine Is Now On Par With The Top 20% Of FDIC-Insured Banks and Savings Institutions Ranked By Deposit Volume

 

 

JERSEY CITY, N.J. — (BUSINESS WIRE) — Bluevine, the one-stop digital banking platform specifically designed for small businesses, on Friday announced it has surpassed $1 billion in managed deposits by its small business banking customers.

 

This significant asset threshold has largely been attracted by Bluevine Business Checking, the company’s unique no monthly fee,1 high-yield SMB checking account with a growing suite of built-in business applications, launched only three years ago – and now puts Bluevine on par with the top 20% of FDIC-insured banks and savings institutions2 ranked by deposit volume, according to the most recent FDIC quarterly report.

Over the past decade since its inception, Bluevine has built a market-leading digital banking platform that has served over 500,000 business owners and delivered more than $14 billion in loans to help simplify financial operations and facilitate access to growth capital for its customers, which have been historically underserved by traditional banks.

 

“We knew that a checking account could be more than just a utility for business owners, and actually evolve into an essential application to run their companies successfully. The Bluevine approach was to provide greater transparency and value by stripping out the extraneous fees and penalties that exist in traditional business banking along with providing high yield on operating balances. In addition, we built a digital-first experience that eliminated the need for even a single branch visit, and integrated a range of sophisticated business features that would empower customers to streamline their financials – supporting the way they prefer to run their companies,” explained Eyal Lifshitz, Co-Founder and CEO of Bluevine.

 

“The introduction of Bluevine Business Checking has filled a long-standing void in the market, evidenced by the steady growth rate of customer accounts, deposits, and payments volume in a relatively short time period. Today marks a significant company milestone – we are humbled by and grateful to our customers for trusting Bluevine with more than $1 billion in managed deposits,” Lifshitz continued.

 

Throughout 2023, Bluevine has added key capabilities to its Bluevine Business Checking account, which offers 2.0% Annual Percentage Yield (APY) on balances up to $250,000,3 with no monthly fees and unlimited transactions as part of its standard plan. Notably, the company recently introduced a small business credit card and launched accounts payable, giving small business owners and their teams sophisticated bill management, automation, user access control, and enhanced payment capabilities. Bluevine also expanded FDIC insurance coverage on balances up to $3 million4 (12x the industry standard of $250,000) and added an international payments and FX solution in partnership with Wise.

 

In November, the company launched Bluevine Premier, providing business owners with all the features of the standard plan, plus the opportunity to earn 4.25% APY on their Bluevine Business Checking balances up to $3 million, along with 50% off most standard plan payments fees, and priority access to customer support. Designed for scaling companies with growing needs, Bluevine Premier provides APY and payment fees on par with commercial offerings that are typically reserved only for large corporations with much higher balances and volumes of transactions compared to a typical small business.

 

Bluevine Premier customers who both maintain a $100,000 minimum average daily balance across their Bluevine Business Checking account and sub-accounts and spend at least $5,000 on their Bluevine Business Debit Mastercard® during each billing cycle incur no monthly fee. Businesses that do not meet these criteria can still benefit from Premier for a monthly fee of $95. Business owners can also take advantage of a one-month free trial for Bluevine Premier.

 

About Bluevine

Bluevine provides a one-stop digital banking platform specifically designed for small businesses. Since launching in 2013, Bluevine’s innovative and intuitive products, including business checking, integrated accounts payable, and lines of credit, have helped over 500,000 business owners save time and money so they can focus on what matters most: growing their business.

 

Bluevine is backed by leading private and institutional investors, including Lightspeed Venture Partners, Menlo Ventures, 83North, Citi Ventures, ION Crossover Partners, SVB Capital, Nationwide Insurance, and M12 (Microsoft’s Venture Arm). Bluevine is a financial technology company, not a bank. Banking Services provided by Coastal Community Bank, Member FDIC. Lines of credit are issued by Celtic Bank, a Utah-chartered Industrial Bank, Member FDIC. For more information, please visit bluevine.com or follow us on LinkedIn, Instagram, Facebook, and Twitter.

 

_________________________

1No monthly fee only applies to the Bluevine Business Checking Account Standard plan.

2FDIC-insured banks and savings institutions include commercial banks or savings institutions that are state or federally chartered.

3Customers will earn 2.0% interest on total balances up to and including $250,000 only if they meet the monthly debit transaction or deposit requirements described in section M of the Account Agreement. No interest earned on balances over $250,000. Any interest accrued and payable for an Account or Sub-Account will be paid to your main Account.

4Bluevine accounts are FDIC insured up to $3,000,000 per depositor through Coastal Community Bank, Member FDIC and our program banks. $3,000,000 in FDIC insurance is offered by multiplying the standard $250,000 FDIC coverage across multiple banks. For complete details, please visit https://www.bluevine.com/business-checking/fdic-protection.

Contacts

Media:

Kevin McLaughlin

Senior Director, PR & Communications

press@Bluevine.com